论文部分内容阅读
目的 评估蛇毒降纤酶治疗急性脑梗死的临床疗效 ,以及患者血纤维蛋白原 ( FIB)的变化 方法 对 30例急性脑梗死患者静脉注射降纤酶 ;同时对 1 5例患者常规使用低分子右旋糖酐和丹参 ,对 2组临床疗效、 FIB改变、不良反应进行对照讨论。结果 降纤酶组显效 8例 ( 2 6 .7% ) ,总有效率 73.3% ;对照组显效 2例 ( 1 3.3% ) ,总有效率 6 0 .0 %。FIB变化 :降纤酶组用药后 FIB显著下降 ,与用药前相比 P<0 .0 1 ,而对照组无变化。结论 降纤酶可以显著降低患者血 FIB含量 ,但近期临床疗效与对照组无显著性差异 ,远期效果有待评价。
Objective To evaluate the clinical efficacy of defibrase in the treatment of acute cerebral infarction and the changes of fibrinogen (FIB) in 30 patients with acute cerebral infarction by intravenous injection of defibrase. At the same time, routine dextran And Salvia, on the clinical efficacy of two groups, FIB changes, adverse reactions were discussed. Results The defibrase group was markedly effective in 8 cases (26.7%), the total effective rate was 73.3%. The control group was markedly effective in 2 cases (13.3%), the total effective rate was 60.0%. FIB changes: defibrase group FIB significantly decreased after treatment, compared with before treatment P <0 01, while the control group unchanged. Conclusion Defibrase can significantly reduce the blood FIB content of patients, but no significant difference between the clinical efficacy and the control group, the long-term results to be evaluated.